Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-VEGF-C monoclonal antibody (Kekkan Biologics)
- Development stage
- Preclinical
- Lead developer
- Kekkan Biologics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Kekkan Biologics is developing a neutralizing monoclonal antibody targeting Vascular Endothelial Growth Factor C (VEGF-C) for the treatment of metastatic cancers, including clear cell renal cell carcinoma (ccRCC). The antibody binds to VEGF-C to inhibit VEGF-C-driven lymphangiogenesis and angiogenesis, thereby preventing tumor metastasis. Developed as a spin-off from the University of Nice Côte d'Azur and the Institute for Research on Cancer and Aging (IRCAN), this biologic has shown efficacy in preclinical models of ccRCC. The company holds patents on these novel anti-VEGFC antibodies and their therapeutic uses in neovascular and fibrotic disorders.
- Other names
- anti-VEGFC antibodyVEGF-C monoclonal antibody
02
Targets
VEGFC (VEGF-C)
Beyond the preview
Go deeper on anti-VEGF-C monoclonal antibody (Kekkan Biologics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-VEGF-C monoclonal antibody (Kekkan Biologics).